Founded in 2013, the Aachen-based medical technology company Hemovent is a developer and manufacturer of ECMO systems for intensive care medicine. Derived from the classic heart-lung machine, this technology takes over the heart and/or lung function of a patient for a few days up to several weeks.

Hemovent on the cooperation with MIG Capital:

“MIG has been a reliable partner and lead investor for us, who has always been at our side with a steady hand and expertise, even in stormy times.” Christof Lenz, CEO and Dr. Oliver Marseille, CTO